Amgen's virus therapy shows survival trend in cancer, faces skeptics
This article was originally published in Scrip
Executive Summary
Amgen’s experimental therapy that uses a modified herpes simplex virus to kill cancer showed a trend toward improved survival in a study of melanoma patients, although the data are not yet mature.